|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/127 | |
| B82Y 5/00 | |||
| A61K 47/69 | |||
| A61P 35/00 |
| (11) | Patento numeris | 2611421 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11822698.4 |
| Europos patento paraiškos padavimo data | 2011-09-02 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-07-10 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2018-10-24 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2011/050287 |
| Data | 2011-09-02 |
| (87) | Numeris | WO 2012/031175 |
| Data | 2012-03-08 |
| (30) | Numeris | Data | Šalis |
| 201113224399 | 2011-09-02 | US | |
| 402686 P | 2010-09-02 | US |
| (72) |
REISFELD, Ralph A., US
XIANG, Rong, US
LUO, Yunping, US
LIAO, Debbie, US
LIU, Ze, CN
CHEN, Tingmei, CN
CHEN, Si, CN
LU, Dan, US
|
| (73) |
The Scripps Research Institute,
10550 North Torrey Pines Road, TPC-9, La Jolla, CA 92037,
US
|
| (54) | NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY |
| NANOPARTICLE-BASED TUMOR-TARGETED DRUG DELIVERY |